RxDoctor Payments Data

Christian Deutsch, MD

Cardiovascular Disease · Huntsville, ALNPI 1740542570

Payments from drug & device makers

$9,100in general payments, 2019–2025

Across 380 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$659
  • Boston Scientific$656
  • Merck$641
  • Amgen$583
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$1,44516%
  • Food & beverage$7,63384%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,100 in reported general payments places this provider in the 70th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$534,003
Medicare patients
769
Services billed
3,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$283,788
XareltoRivaroxaban111$99,519
FarxigaDapagliflozin Propanediol40$30,135
EntrestoSacubitril/Valsartan35$30,001
Repatha SureclickEvolocumab34$26,505
MultaqDronedarone Hcl11$19,050
Metoprolol Succinate404$5,757
Flecainide Acetate95$5,663
Propafenone Hcl ErPropafenone Hcl23$5,526
Ranolazine ErRanolazine54$4,709
Atorvastatin Calcium201$2,714
Isosorbide Mononitrate ErIsosorbide Mononitrate135$2,196
Nebivolol Hcl38$1,882
Cilostazol70$1,788
Losartan Potassium156$1,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$348$283,788295 claims
Johnson & JohnsonXarelto$182$99,519111 claims
AstraZenecaFarxiga$248$30,13540 claims
NovartisEntresto$456$30,00135 claims
Sanofi-aventis U.S. LLCMultaq$212$19,05011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →